免疫检查点抑制剂在肝细胞癌治疗中的应用与展望
摘要
<正>免疫检查点(Immune checkpoint)抑制剂是近年来肿瘤免疫治疗领域取得的重大突破。免疫检查点是指T细胞表面存在的一些抑制性受体,当其与抗原递呈细胞上的配体结合后可抑制T细胞的功能。人体主要的免疫检查点有两个:细胞毒T淋巴细胞抗原4(CTLA-4)和程序性死亡因子1(PD-1)。CD28及其配体是抗原提呈细胞表面的B7分子,两者结合产生协同刺激信号,诱导T细胞活化。CTLA-4与CD28阳性T细胞有共同的配体B7-1和B7-2
引文
[1] El-Khoueiry AB,Sangro B,Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial.Lancet,2017,389:2492-2502.
[2] Hui E,Cheung J,Zhu J,et al.T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.Science,2017,355:1428-1433.
[3] Kim HD,Song GW,Park S,et al.Association Between Expression Level of PD1 by Tumor-Infiltrating CD8(+) T Cells and Features of Hepatocellular Carcinoma.Gastroenterology,2018,155:1936-1950.
[4] Lake AC.Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy.AIDS 2017,31:2115-2118.
[5] Zhu AX,Finn RS,Edeline J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224):a non-randomised,open-label phase 2 trial.Lancet Oncol,2018,19:940-952.
[2] Hui E,Cheung J,Zhu J,et al.T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.Science,2017,355:1428-1433.
[3] Kim HD,Song GW,Park S,et al.Association Between Expression Level of PD1 by Tumor-Infiltrating CD8(+) T Cells and Features of Hepatocellular Carcinoma.Gastroenterology,2018,155:1936-1950.
[4] Lake AC.Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy.AIDS 2017,31:2115-2118.
[5] Zhu AX,Finn RS,Edeline J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224):a non-randomised,open-label phase 2 trial.Lancet Oncol,2018,19:940-952.